Fortis Healthcare Ltd on Friday announced that the Competition Commission of Singapore has ruled against its proposed divestment of 100% stake in its Singapore-based diagnostic and molecular imaging unit RadLink.
In its review of the proposed transaction, the commission cited the possible lessening of competition in the relevant market as the reason for its disapproval of the deal, Fortis said in a filing to stock exchanges. “Our step down subsidiary at Singapore, Fortis Healthcare Singapore Pte. Ltd has received a decision from the Competition Commission of Singapore wherein following a review of the proposed transaction, involving the acquisition of RadLink-Asia Pte Limited and its subsidiaries by Medi-Rad Associates Ltd, an indirect wholly owned subsidiary of IHH Healthcare Berhad, the regulator has indicated that if the proposed transaction is completed as contemplated, the combination may result in lessening of competition in the relevant market in Singapore,” the statement said.
Full Content: The Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI